Johnson & Johnson (NYSE: JNJ) is one of the world's largest healthcare companies, focused on innovative medicine — oncology, immunology, neuroscience — and MedTech across surgery, orthopaedics, cardiovascular and vision. It has raised its dividend for more than 60 consecutive years.
After spinning Band-Aid, Tylenol and Listerine into Kenvue in 2023, JNJ's mix became roughly two-thirds innovative medicine and one-third MedTech. Gross margin and R&D intensity rose, but so did exposure to patent cliffs, drug-price negotiation and clinical readouts. JNJ should now be judged much more like a large-cap pharma company.
Oncology (Darzalex, Carvykti, Erleada) sets the pace for pharma growth. Immunology is transitioning from Stelara, which faces biosimilar erosion, toward Tremfya. MedTech benefits from recovering procedure volumes and ageing demographics, while strong free cash flow funds the dividend, buybacks and deals such as Abiomed and Shockwave.
Loss of exclusivity on blockbusters must be filled quickly by new launches. Talc litigation has weighed on the multiple for years. U.S. Medicare price negotiation squeezes mature drug pricing, and trial failures or poorly integrated acquisitions can undo growth assumptions.
Carvykti capacity expansion and earlier-line use are elastic growth levers. Electrophysiology plus Shockwave and Abiomed add high-price procedure consumables. Joint replacement, cataract and chronic-disease demand rises with the global over-65 population.
JNJ compounds through defensive cash flow and a dividend raised every year and reinvested. Track oncology growth, the real pace of Stelara erosion, and MedTech operating margin.
Note: Figures assume dividends are reinvested (DRIP). JNJ has raised its dividend for more than 60 consecutive years and the 2023 Kenvue separation is reflected in adjusted historical returns. Past performance is not a guarantee of future results. Data updates daily.